The hepatitis B virus X protein (HBx) is thought to be implicated in the development of hepatocellular carcinoma, but its exact function remains controversial. Transgenic mice from PEX7 and AX16 lineages that express HBx in the liver under control of dierent viral regulatory elements develop no liver pathology (Billet et al., 1995) . We have crossed these two mouse lineages with WHV/c-myc oncomice in which liver-speci®c expression of c-myc driven by woodchuck hepatitis virus (WHV) regulatory sequences causes liver cancer in all animals. The average tumor latency was shortened by 2 to 3 months in bitransgenic animals from all populations compared with simple c-myc transgenic littermates. At preneoplastic stages, adult bitransgenic mice showed four to ®vefold enhanced expression of the c-myc transgene, increased hepatocyte proliferation and more extensive liver lesions compared with simple WHV/c-myc transgenics. Thus in this model, HBx alone has no direct pathological eect but it is shown to accelerate tumor development induced by c-myc. The data presented here ®rmly establish the oncogenic potential of HBx, apparently acting as a tumor promoter. This model oers unique opportunities to investigate the mechanisms by which HBx trans-activates the expression of target genes and deregulates the hepatocyte growth control in vivo.
Introduction
Hepatitis B virus (HBV) is a major causative agent of acute and chronic hepatitis in humans worldwide. Despite overwhelming epidemiological evidence linking persistent HBV infection and the development of hepatocellular carcinoma (HCC) (Beasley et al., 1981) , the mechanisms by which the virus contributes to liver cell transformation remain elusive. Inspection of cloned HBV genomes revealed four overlapping reading frames conserved among dierent genotypes, that encode virion structural proteins (the surface and core antigens) and proteins implicated in viral replication (the DNA polymerase and the X transactivator protein, HBx). None of these viral gene products has proved to behave as a dominant oncogene, and it is generally agreed that HBV can neither directly nor acutely transform liver cells.
Studies of HBV-related animal viruses have strengthened the link between HBV and HCC and shed some light on the mechanisms operating in malignant conversion of infected hepatocytes (reviewed in Buendia, 1992) . The woodchuck and ground squirrel hepatitis viruses have been associated with hepatocarcinogenesis in the rodent hosts (Marion et al., 1986; Summers et al., 1978) . In contrast, the oncogenic potential of avian hepadnaviruses, that are devoid of an X open reading frame, has not been conclusively established (Du¯ot et al., 1995) . This led to suggest that X gene products from mammalian hepadnaviruses might play a role in liver carcinogenesis. During the last decade, seemingly contradictory data have accumulated on HBx function in natural infections. At least, two salient features of the hepadnavirus X gene products deserve consideration. On one hand, the requirement for a functional X gene in the establishment of viral infection in woodchucks has been ®rmly established Zoulim et al., 1994) , although the exact role of the X protein in viral replication is still unknown. On the other hand, HBx transcriptional trans-activation properties have been demonstrated on a variety of viral and cellular regulatory elements (Au®ero et al., 1990; Spandau et al., 1988; Twu et al., 1987) . Noticeably, trans-acting activity of HBx was rather weak (510-fold activation) in most experimental systems used, and it has not been demonstrated so far in the context of the whole viral genome. HBx does not directly bind DNA and may stimulate gene expression by interacting with transcriptional factors or with elements of the basal transcription machinery (Cheong et al., 1995; Haviv et al., 1995; Maguire et al., 1991; Qadri et al., 1995; Unger et al., 1990; Williams et al., 1995) . Other studies support an indirect eect of HBx by activating signalling pathways mediated by the Ras-Raf-MAPK cascade or by protein kinase C, a function consistent with the predominant cytoplasmic location of HBx in vivo and in most experimental systems (Benn et al., 1994; KekuleÂ et al., 1993; Natoli et al., 1994) .
Arguments favoring a signi®cant role of HBx in liver cancer were provided by studies of HBV-related tumors and in experimental models. Integrated HBV sequences in tumor DNA are frequently interrupted between the viral direct repeats DR1 and DR2 (Nagaya et al., 1987) , generating 3' truncated versions of the X gene that retain trans-activating capacity (Koshy et al., 1991; Takada et al., 1990; Wei et al., 1995; Wollersheim et al., 1988) . Moreover, in HCC patients negative for the HBV surface antigen, accumulation of viral RNAs containing X but not surface or core sequences was evidenced by polymerase chain reaction (PCR) (Paterlini et al., 1995) . This suggests that the integrated X gene may be important for maintaining the tumor phenotype at early stages of carcinogenesis. It has been reported that HBx binds the tumor suppressor p53 protein and inactivates its functions (Feitelson et al., 1993; Truant et al., 1995; Wang et al., 1994) . Interaction of HBx with XAP-1, a cellular DNA repair protein homologous to the monkey u.v.-damaged DNA-binding protein, might aect cell ability to repair mutated DNA sequences and allow the accumulation of genetic changes (Lee et al., 1995) . Another potential target of HBx was identi®ed with XAPC7, a novel proteasome subunit; this interaction may be functionally relevant to the pleiotropic action of HBx (Huang et al., 1996) . However, evidence for a direct oncogenic eect of HBx in vivo is scarce. HBx expression can transform rodent hepatocytes immortalized with the SV40 large T antigen (HoÈ hne et al., 1990) . In a transgenic mouse line generated in the outbred CD1 background, high level expression of HBx in the liver induced the progressive appearance of altered hepatocyte foci, proliferative adenomatous nodules, and malignant carcinomas that killed most male animals before 15 months of age (Kim et al., 1991) . In contrast, a second mouse lineage with lower HBx expression developed liver tumors at the same rate as normal CD-1 mice (Koike et al., 1994) , and other HBx transgenic lines generated in dierent mouse strains developed no obvious hepatic pathology, although the HBV X gene was expressed in liver cells and the HBx protein could be detected in some cases Billet et al., 1995; Lee et al., 1990; Perfumo et al., 1992; Yen, 1996) . Similarly, the related X protein of WHV (WHx) had no apparent oncogenic potential by itself when expressed in transgenic mouse liver; it was shown to enhance the occurrence of preneoplastic lesions in mice treated with diethylnitrosamine (Dandri et al., 1996) . These data suggest that the hepadnavirus X protein has no acutely transforming activity, but its overexpression in the susceptible CD-1 mouse strain might cooperate with activated cellular oncogene(s) in multistep hepatic transformation. Moreover, recent studies of the expression of the WHx protein in chronically infected woodchuck livers and in HCCs suggest that it may play a role at an early stage of the oncogenic process, but is not required to maintain a malignant phenotype (Dandri et al., 1996) .
In this report, we have analysed the oncogenic potential of HBx by crossing transgenic mice from PEX7 and AX16 lineages that develop no pathology with WHV/c-myc transgenic mice highly predisposed to liver cancer. We ®nd signi®cant acceleration of the tumorigenic process, associated with upregulation of cmyc and increased hepatocyte turnover in the livers of bitransgenic animals.
Results

HBV X gene expression in PEX7 and AX16 mice
Transgenic mice expressing HBX mRNA in the liver (designated PEX7 and AX16) have been described Billet et al., 1995) . Neither of these transgenic lines have developed any pathology over two years of observation. A schematic representation of the PEX7 and AX16 transgenes and the RNAs produced from multiple transgene copies inserted in tandem array is given in Figure 1a . Abundant Xspeci®c mRNAs of 0.8 and 1.8 kb were detected in the livers of PEX7 and AX16 mice during the perinatal period by Northern hybridization of total liver RNA with a HBX probe (Figure 1b) . In a previous report, transcription was shown to initiate preferentially at the X promoter in PEX7 mice, and curiously, at the HBV (Galibert et al., 1979) . Transcripts arising from multiple copies of the transgenes integrated in tandem array are depicted under the corresponding DNA region (Billet et al., 1995) . (b) Northern analysis of HBX transgene expression during post-natal liver development. Twenty mg of total RNA isolated from AX16 and PEX7 livers at dierent ages as indicated were separated on agarose gels, transferred onto nylon membranes and hybridized with a X-speci®c probe. Loading of equivalent amounts of RNA was controlled by ethidium bromide staining of ribosomal RNA. (c) Western blot showing weak expression of the HBx protein in 10-day-old transgenic livers. Western blotting was performed on total cell extracts prepared from CCL13 cells (lane 1), CCL13 cells transiently transfected with a HBX/¯ag fusion gene driven by the CMV promoter (lane 2), and from the livers of 10-day-old PEX7 transgenic mice (lanes 4 and 6) and nontransgenic littermates (lanes 3 and 5) as described in Materials and methods. The blot was probed with a polyclonal anti-HBx antibody and revealed using alkaline phosphatase-conjugated secondary antibodies and Western-star chemiluminescence reagents core gene promoter in AX16 mice, in which the ATIII promoter remained silent (Billet et al., 1995) . Minor RNA species of larger sizes resulted from leaky transcription termination at the HBV polyA signal. In mouse livers from both lineages, the levels of X mRNAs gradually declined as the animals aged, reaching very low levels at the adult stage ( Figure  1b) . By Western blotting of total liver cell proteins, a polypeptide of 16 kDa was detected at low levels in 10-day-old PEX7 and AX16 mouse livers, but not in adult transgenic mice nor in nontransgenic controls, using a polyclonal antiserum raised against the HBx antigen ( Kay et al., 1991) , as illustrated for PEX7 mice in Figure 1c . A normal rabbit serum revealed no signal at the corresponding position (data not shown). 
Liver tumors develop more rapidly in WHV/c-myc mice when crossed with HBX transgenics
In other published lineages that similarly develop no spontaneous malignancy, HBx was shown to increase cellular susceptibility to chemical hepatocarcinogens (Slagle et al., 1996 and M Tripodi, unpublished results) , suggesting that HBx may act as a co-factor in liver oncogenesis. This led us to investigate whether HBx could cooperate with a dominant oncogene in hepatocarcinogenesis. Recently, we generated transgenic mice carrying the c-myc gene and nearby integrated WHV sequences isolated from a woodchuck HCC (Etiemble et al., 1994) . In two dierent lineages (93-7 and 93-10), liver tumors developed almost invariably, despite temporally limited expression of the woodchuck c-myc transgene in the neonatal liver. Previously noted dierences in tumor kinetics between the 93-7 and 93-10 lineages (average 8 months versus 12 months) have been attributed to higher copy number and additional rearrangements of the transgene in the former.
Transgenic mice from the AX16 and PEX7 lineages were crossed with 93-10 WHV/c-myc mice, and PEX7 mice were crossed with 93-7 mice. Although the parental lineages were maintained mostly through backcrosses with C57BL/6 inbred mice, slightly divergent genetic backgrounds (see Materials and methods) might interfere with individual susceptibility to cancer development. We therefore set up crossing experiments between heterozygous carriers of HBx and c-myc transgenes from three dierent generations to produce ospring either heterozygous for one or two transgenes, or nontransgenic. All animals were examined by weekly palpation and sacri®ced when presenting clinical signs of liver tumors. As shown in Figure 2 , HCCs were detected earlier in bitransgenic animals carrying either PEX7 or AX16 transgenes than in simple WHV/c-myc littermates. All bitransgenic animals developed large HCCs within less than 60 weeks. Fifty percent of PEX7693-10 and AX16693-10 bitransgenic animals developed liver tumors by 38 weeks of age (T 50 ) (compared with simple 93-10 mice in which T 50 =48 and 52 weeks). Similarly, the T 50 of PEX7693-7 bitransgenics was 33 weeks, while that of simple 93-7 mice was 41 weeks (Figure 2c ). Thus, HCC formation was accelerated to a similar extent (by 8 to 14 weeks) in WHV/c-myc animals carrying the PEX7 and AX16 transgenes. These data were found to be statistically signi®cant (P50.05) in each bitransgenic group by using the Mann ± Whitney's non-parametric test.
Importantly, the population of WHV/c-myc mice that did not carry an HBX transgene developed tumors at the same rate as the parental population (Etiemble et al., 1994) . Therefore, breeding with PEX7 or AX16 mice did not modify the susceptibility of WHV/c-myc mice to HCC development, which clearly implicates the HBX transgenes in the observed acceleration of tumor formation. Whether earlier detection of advanced stage Figure 2 Kinetics of tumor occurrence in HBX6WHV/c-myc bitransgenic mice. The percentage of tumor-free animals as a function of age is shown in (a) for mice resulting from crossings between AX16 and WHV/c-myc 93-10 mice, in (b) for PEX76WHV/c-myc 93-10 mice, and in (c) for PEX76WHV/cmyc 93-7 mice. Animals were sacri®ced when they became terminally ill and post-mortem examination was carried out. n is the number of animals in each population tumors in dual-positive animals re¯ected earlier tumor onset or increased proliferation of neoplastic cells was not determined. Liver tumors, predominantly well dierentiated HCCs of the trabecular type, were indistinguishable from those previously described in the parental WHV/c-myc lineages (Etiemble et al., 1994) , and none of the animals examined showed other neoplasms. Moreover, Southern blot analysis of liver and tumor DNAs from simple and double-transgenic animals did not reveal any gross rearrangement of the WHV/c-myc transgene (data not shown). Finally, consistent with the largely predominant C57BL/6 background of all lineages, none of the nontransgenic animals analysed in the present study (n=35) developed any type of cancer over 2 years of observation.
Activation of WHV/c-myc transgene expression in adult bitransgenic mice
In WHV/c-myc mice, liver-speci®c expression of the transgene gives rise to two dierent transcripts: a normal 2.5 kb c-myc mRNA driven by the c-myc P1 promoter, and a 1.8 kb WHV transcript initiated at a viral preS2/S promoter (Wei et al., 1996) (Figure 3a) . Expression of the WHV/c-myc transgene was assessed in PEX7693-10 double transgenic and in 93-10 simple transgenic littermates at dierent ages by Northern hybridization of total liver RNA with a woodchuck cmyc exon 1 probe, used under stringent hybridization conditions, and with WHV DNA. As shown in Figure  3b , high steady-state levels of woodchuck c-myc and WHV mRNAs were detected during the ®rst month of birth in WHV/c-myc transgenics. These mRNAs were produced in a strictly co-regulated fashion suggesting a predominant control of viral regulatory sequences. The speci®city of the woodchuck c-myc exon 1 probe was con®rmed by hybridization of the blots with the corresponding murine c-myc exon 1 probe, which detected very low levels of endogenous c-myc mRNAs (data not shown). HBx expression had no detectable eect on WHV/c-myc transgene expression in the neonatal liver (Figure 3b) . At older ages, transgene expression was strongly down-regulated in simple WHV/c-myc transgenics as described previously (Etiemble et al., 1994) . In contrast, bigenic animals at 60 and 80 days of age still expressed WHV and c-myc transcripts at detectable levels (Figure 3b and c) . Quantitative analysis of the hybridization signals indicated that both c-myc and WHV-speci®c mRNAs were elevated by four to ®vefold in adult bigenic mice compared with simple WHV/c-myc littermates. Signi®cantly, these data were reproducibly observed when 80-day-old animal pairs from six dierent litters were analysed in parallel (Figure 3c ). At this age, X mRNAs were produced at low levels in PEX7 and AX16 mice (see Figure 1b) as well as in double-transgenic animals (data not shown).
Increased cell proliferation and morphological alterations in bitransgenic mouse livers at preneoplastic stages
To better de®ne the eects of HBx expression at preneoplastic stages, the rates of hepatocyte proliferation and apoptosis were assessed in simple WHV/c-myc and double transgenic mouse livers at dierent ages. We determined the proliferation index by counting BrdUlabeled S-phase hepatocytes, and the rate of cells undergoing cell death by in situ DNA nick end-labeling (Gavrieli et al., 1992) . As shown in Figure 4a , proliferation of liver cells was twofold higher in 10 day-old WHV/c-myc transgenics than in nontransgenic littermates (mean values: 20.2+5.5% vs 11.3+1.7%, P50.05), and reached approximately the same value (18.2+4.5%, P50.01) in PEX7693-10 bigenic animals. As the animals aged, hepatocyte proliferation decreased progressively in all populations but remained significantly higher in simple c-myc and bitransgenic animals than in nontransgenic controls. At 80 days, liver cell proliferation was three times higher in WHV/c-myc mice than in controls (mean values: 1.7+0.7% vs 0.5+0.1%, P50.05) (Figure 4d ). The rate of BrdU-positive cells was further increased by twofold (2.9+1.2%) in PEX7693- (61000) showing simultaneous nuclear staining and apoptotic morphology were counted, as shown in Figure 4f . The percentage of apoptotic cells was not further increased (0.36+0.12%) in the livers of PEX7693-10 bigenic neonates. At the adult stage, no signi®cant variation was detected in our assays in the rate of apoptotic hepatocytes among the dierent groups (0.4 to 0.5%, Figure 4b ). We also compared the liver/body weight ratios of WHV/c-myc mice and PEX76WHV/c-myc bitransgenics at dierent ages. A reproducible increase (about 20%) in the liver/body weight ratio of transgenic compared with nontransgenic animals was seen in both cases at all ages tested (data not shown). This suggests that proliferative pathways are predominant over apoptotic pathways in these livers.
Histological examination of liver sections from WHV/c-myc monotransgenic and X/myc bitransgenic animals revealed no gross abnormality in liver architecture before 30 days, although a marked increase in mitotic ®gures and apoptotic bodies was noted (Figure 5a and b) . At older ages, signi®cant dierences were observed in the extent and severity of liver lesions between simple and double transgenic mice. At 80 days, hyperplastic nodules could be seen in double transgenic mice whereas only anisocaryosis, anisocytosis, mitosis and apoptotic bodies were seen in WHV/c-myc animals (Figure 5c and d) . A comparison of the lesions per unit cross-sectional liver area revealed that they increased more rapidly in double transgenic mice. This increase could result from enhanced initiation of foci or the more rapid growth of these foci, making their identi®cation easier.
Discussion
Transgenic mice have been instrumental in demonstrating the requirement for cooperative oncogenic events in cell transformation (Adams et al., 1991) . Liver tumors usually occur after a long latency period in mice carrying a c-myc transgene, making them ideal tools in crossing experiments with mice bearing potentially cooperating genes. A representative example is the synergistic action of c-myc and transforming growth factor a (TGFa) in hepatic oncogenesis (Murakami et al., 1993; Sandgren et al., 1993) . To characterize the eects of the HBV X protein during multistage carcinogenesis, we have crossed HBX transgenic mice with WHV/c-myc mice and examined tumor development in liver of dual-positive animals. The data presented here demonstrate that coexpression of the HBV X gene with c-myc induced a more rapid development of liver tumors than did expression of cmyc alone, thereby reducing the host life span up to 25%. These ®ndings clearly attribute a role to HBx in liver carcinogenesis.
The fact that HBx by itself was largely nononcogenic in PEX7 and AX16 transgenic mice con®rms previous reports showing that transient or low level expression of the X gene was insucient to induce hepatic oncogenesis in transgenic animals (Dandri et al., 1996; Koike et al., 1994; Lee et al., 1990; Perfumo et al., 1992) . In our model, cooperation with a cellular oncogene was required to reveal the oncogenicity of HBx. Similarly, the transforming potential of dierent cellular and viral genes, like cyclin D1, Tal1 and the tax gene of HTLV1, only came to light when coexpressed with a dominant oncogene in double transgenic animals (Benvenistry et al., 1992; Larson et al., 1996; Lovec et al., 1994) . The notion that HBx acts as a tumor promoter in liver oncogenesis was ®rst suggested by its eects on mouse liver susceptibility to chemical hepatocarcinogens (Slagle et al., 1996 and M Tripodi, unpublished results) . It is further supported by the present ®nding that combined expression of the HBX and c-myc genes produced a marked growth response in the entire liver together with extensive hepatic lesions at preneoplastic stages. These eects of HBx might result either from direct or indirect activation of the WHV/c-myc transgene expression, or from an independent pathway leading to altered hepatocyte turnover.
The coordinated increase of woodchuck c-myc and WHV RNA levels in adult livers from double transgenic mice may re¯ect a direct, trans-acting action of HBx on a common regulatory element controlling both mRNA species. In the absence of the potent WHV enhancer II in the WHV/c-myc transgene, one candidate element lies in the region homologous to the HBV enhancer I. This WHV domain carries a 33 bp sequence perfectly conserved between mammalian hepadnaviruses, comprising a composite binding area for transcription factors from the CREB/ATF, C/EBP, and AP1 families, and a strong X-responsive element (Faktor et al., 1990a,b; Unger et al., 1990) . The strict conservation of this motif between HBV and WHV genomes suggests that HBx might be active as well as the WHV enhancer; interspecies activity of the hepadnaviral X proteins has been previously demonstrated in transient transfection assays (Colgrove et al., 1989; Wei et al., 1995) . It has been shown that HBx interacts with and increases the anity of CREB for its cognate binding site in the HBV enhancer I (Maguire et al., 1991; Williams et al., 1995) . This eect presents similarities with that of the transcriptional activator tax on the long terminal repeat of HTLV1 (Kwok et al., 1996) . It is plausible, therefore, that HBx might activate WHV regulatory sequences through a cAMP-regulated enhancer element, in turn activating expression of the WHV/c-myc transgene in the adult, but not in the neonatal liver. In previous studies, the transcriptional trans-activation properties of HBx in vivo were demonstrated in AX16 mice using an HIV LTR-bgalactosidase reporter .
Alternatively, HBx might in¯uence tumor development by more indirect ways, and enhanced expression of the c-myc transgene in bitransgenic livers might be linked to marked preneoplastic changes observed in adult animals. Seemingly contradictory eects of HBx were recently reported: activation of cell cycle progression by deregulating checkpoint controls (Benn et al., 1995) , inhibition of apoptosis through interaction with p53 (Wang et al., 1995) and induction of apoptosis by activating the Ras pathway (Yen, 1996) . Interestingly, some cellular genes such as c-myc may trigger either proliferative or apoptotic responses, depending on the cellular context (Harrington et al., 1994) . Here we show that expression of c-myc in the liver of simple WHV/cmyc transgenics not only promotes cell proliferation, but also slightly increases the rate of hepatocyte death. It will be interesting to determine whether HBx interferes with one or the other c-myc-mediated pathway. Studies of the hepatocyte turnover in PEX7 and AX16 transgenic mice and of the cellular eectors of HBx action would help to clarify the mechanisms by which HBx sensitizes liver cells to malignant transformation.
The role of HBx in the development of liver cancer in HBV-infected patients is a debated question. Previous studies of the X gene function in vitro have shown its ability to activate the Ras-Raf-MAP kinase cascade and to trans-activate cellular genes implicated in growth control (Avantaggiati et al., 1993; Balsano et al., 1991; Benn et al., 1994 Benn et al., , 1996 Twu et al., 1993) . In human hepatocarcinogenesis, overexpression of c-myc is commonly observed both at tumoral and pretumoral stages, whereas c-myc expression is barely detectable in the normal adult liver (Gu et al., 1986; Himeno et al., 1988; Zhang et al., 1990) . Our evidence that co-expression of the HBx and c-myc transgenes accelerated HCC development in transgenic mice clearly establishes the viral transactivator as a tumor promoter and as a cooperating partner of the c-myc oncogene in liver cell transformation. This and other studies of transgenic models provide a basis to de®ne the contribution of HBx in altered gene expression and deregulated cell growth during multistage carcinogenesis.
Materials and methods
Experimental animals
AX16 and PEX7 transgenic mice carry the HBV X open reading frame as described Billet et al., 1995) . The chimeric 1.7 kb AX transgene contains human antithrombin III regulatory sequences (R allele of the ATIII gene) linked to the X coding sequence from HBVayw and the HBV polyadenylation signal. The PEX transgene was a 1172 bp AccI ± BglII fragment of the HBVayw genome, spanning the enhancer I/X promoter, the X open reading frame, and the viral polyadenylation signal (see Figure 1a) . Both lineages were produced on a C57B1/66DBA2 hybrid background. WHV/c-myc transgenic mouse lineages 93-7 and 93-10 were described (Etiemble et al., 1994) . Brie¯y, the transgene, a 14 kb DNA fragment spanning the entire c-myc gene and adjacent integrated WHV sequences cloned from a woodchuck HCC (see Figure 3a) , was microinjected in C57Bl/66SJL/J hybrid embryos. Transgenic founders and progeny were backcrossed for ten or more generations with either inbred C57Bl/6 mice or transgenic littermates. Transgenic mice were identi®ed by hybridization of tail biopsy DNA with transgene-speci®c probes. For X transgenics, the probe was derived from a PCR fragment spanning 420 bp of the HBVayw X open reading frame (positions 1375 ± 1795 on the HBV map) (Galibert et al., 1979) . For WHV/c-myc mice, we used a PCR fragment covering 320 bp of the WHV genome (nt 1158 ± 1478) (Galibert et al., 1982) . Animals were handled and euthanized according to French government guidelines (MinisteÁ re de l'Agriculture, Services VeÂ teÂ rinaires de la SanteÂ et de la Production Animale).
Liver examination
Mice were examined at weekly intervals and sacri®ced at dierent ages (days 10, 20, 30 and 80 after birth) for biological and histological analyses, or at later stages when abdominal broadening provided evidence of liver tumors. Complete autopsies were performed, and gross and microscopic evaluations were done. For histological examination, liver specimens were ®xed in Bouin's¯uid, embedded in picolyte-paraplast, sectioned at 5 mm and stained with hematoxilin-eosin.
In vivo labeling of S-phase hepatocytes 5-bromo-2'-deoxyuridine (BrdU) was used for non-isotopic S-phase labeling of hepatocytes. BrdU (Sigma Chemical Co) was dissolved in sterile phosphate buered saline (PBS) and injected intraperitoneally 2 h before sacri®ce at a dose of 100 mg/kg. At sacri®ce, total mouse bodies and isolated livers were weighted, and liver lobes were ®xed in 4% paraformaldehyde (Flucka), then in ethanolamine 0.1 M pH 7.4 (Flucka) and embedded in paran. Five mm thick sections were ®rst treated with 3% hydrogen peroxide for 30 min to block endogenous peroxidase activity, and then digested with 0.1% trypsin in 0.2 M TrisHCl pH 8 for 10 min at 378C. A mouse monoclonal antibody against BrdU (Immunoglobulin G, Pharmingen, San Diego, CA) was applied at 1 mg/ml for 2 h at room temperature. The primary antibody was then detected by a sheep anti-mouse biotinylated secondary antibody (Large Volume DAKO LSAB Kit, Dako, Carpinteria, CA) according to manufacturer's instructions. Metal-enhanced 3,3'-diaminobenzidine was used as the ®nal color-reaction product. Cell nuclei were counterstained with hematoxylin.
Detection of apoptotic hepatocytes
Liver sections ®xed as described above were ®rst treated with 20 mg/ml proteinase K for 15 min at room temperature. 3'-OH DNA termini were nick-end labeled using 1 unit of terminal deoxynucleotidyl transferase and 1.5 nmol of biotin-16-dUTP in 50 ml TdT buer, for 1 h at 378C (`TUNEL' method; all reagents were supplied by Boehringer Mannheim Biochemical). Slides were incubated for 15 min at room temperature in terminal buer (300 mM NaCl, 30 mM sodium citrate, RT), rinsed in H 2 O and then saturated for 10 min in 2% BSA. Samples were stained in the dark with 2% ExtrAvidin-TRITC conjugate for 40 min at room temperature (Sigma Chemical Co, France). Finally, slides were rinsed in H 2 O and nuclei were stained with hematoxylin before mounting.
Quantitative morphometry
The slides were observed with a conventional light and u.v. Leitz microscope (original magni®cation 6400 or 61000 under oil immersion). For S-phase quanti®cation, 10 consecutive optic ®elds were counted for each liver section (about 1000 hepatocytes). For apoptotic quanti®cation, 20 consecutive optic ®elds were counted. Only the¯uorescent signals showing a typical morphology of apoptotic hepatocytes were selected. The S-phase labelling rate was expressed as the percentage of total hepatocytes containing BrdU-positive nuclei. The apoptotic rate was expressed as the percentage of total hepatocytes containing stained nuclei. Data were analysed statistically using the Kruskall ± Wallis or Mann ± Whitney's non-parametric tests. A level of 5% probability was considered statistically signi®cant. All values are given as mean+s.d.
DNA and RNA analysis
Frozen liver samples were crushed in liquid nitrogen and used for DNA or RNA extraction as described previously (Wei et al., 1992) . For Southern blot analysis, total genomic DNA (20 mg) was digested with NcoI, separated on 0.8% agarose gels and transferred to nylon membranes (Hybond N + , Amersham) in 0.4 N NaOH. For Northern blot analysis, total RNA (20 mg) was denatured with glyoxal and dimethylsulfoxyde, electrophoresed through 1% agarose gels, and transferred onto Hybond N + in 0.05 N NaOH. The integrity and relative amounts of RNA were checked by ethidium bromide staining of ribosomal RNAs. Hybridizations of Southern and Northern blots were carried out according to (Church et al., 1984) , using probes labeled by random priming. The following probes were used: cloned WHV DNA (Ogston et al., 1982) , a 1.4 kb BglII fragment speci®c for woodchuck c-myc exon 1 (MoÈ roÈ y et al., 1985) , a murine c-myc exon 1 probe (Stanton et al., 1984) , a PCR fragment spanning 420 bp of the HBVayw X open reading frame (positions 1375 ± 1795 on the HBV map) (Galibert et al., 1979) , and a mouse actin cDNA. After hybridization with the c-myc probes, ®lters were washed under conditions of high stringency (0.16SSC, 0.1% SDS, 658C for 1 h). Labeled bands were quanti®ed directly with a PhosphoImager (Molecular Dynamics), and standardized with the actin probe. The blots were exposed to XAR-5 ®lms (Kodak) at 7808C with intensifying screens.
Western blot analysis
Total cell extracts were prepared from AX16 and PEX7 transgenic and nontransgenic livers as previously described (Etiemble et al., 1994) . Brie¯y, fresh liver tissues were homogenized in protein lysis buer (50 mM Tris (pH 8), 150 mM NaCl, 1% Nonidet P-40, 0.1% SDS, 0.5% sodium deoxycholate, 2 mM phenylmethylsulfonyl¯uoride, 1 mg/ml leupeptitine and pepstatin). Cell lysates prepared by the same method from CCL13 cells were kindly provided by C Transy and S Pringent. Twenty mg of proteins were subjected to electrophoresis through 16.5% acrylamide gels, and the resolved proteins were transferred to a Hybond C extra membrane (Amersham) using the Transblot semi-dry apparatus (Biorad). The HBx protein was detected with a polyclonal anti-X serum (1 : 3000 dilution; a kind gift of A Kay) using the Western-star chemiluminescent detection system (Tropix) according to manufacturer's instructions.
